Cell Manufacturing Technologies
Transforming the manufacture of cell-based therapeutics into a large-scale, lower-cost, reproducible, and high-quality engineered process, for broad industry and clinical use.
Specifially, three Engineered Systems (Test-Beds) are envisioned:
- Mesenchymal Stem/Stromal Cells (MSCs) to repair, regenerate, and restore diseased tissues and organs
- T cell immunotherapies to cure cancer
- Induced Pluripotent Stem Cell-derived cardiac cells (iPSC-CM) to treat heart diseases
In each of these Test-Beds, CMaT will focus on three, synergistic technical innovation Thrusts: c
THRUST 1
Cell-omics for biomarker discovery
- Identification of predictive biomarkers
- Benchmarks of efficacy, safety, potency
- Targeted assay development for CQA
- Integration of several state-of-the-art analytical platforms
- Computational models of interactions across heterogeneous data using novel methods
- Train diverse, interdisciplinary engineering workforce in cell therapy manufacturing
THRUST 2
Rapid and reliable assessment of cell quality, i.e. potency and safety
- Engineer reproducible, predictive measurement and assay technologies that enable batch & continuous monitoring of cell state and product
- Non-destructive, in-line, closed system analysis using real-time sampling, reporters/sensors and imaging tools
- “Potency-on-a-chip” 3D disease and organoid models
- Train a diverse and interdisciplinary workforce in cell manufacturing
THRUST 3
Process and systems engineering for scale-up or scale-out manufacturing
Major objectives include developing closed culture systems that utilize data from real-time sensors to improve potency and reduce variability in quality/quantity of the cellular product during culture and generating robust supply chain and process modeling algorithms to ensure product reproducibility and cost-effectiveness.
Notice: Please contact international@erc-assoc.org if you represent this Research Institution and have identified any required additions or modifications to the above information.